Pharmacy Drugs
Recent Posts
- Small Molecules Found To Protect Cells In Multiple Models Of Parkinson’s Disease
- Arena Pharmaceuticals Announces Merck Discontinues Development Of Investigational Niacin Receptor Agonist Program For Atherosclerosis
- Soligenix Announces Publication Of Positive Pre Clinical Results With RiVax(TM), Its Vaccine Against Ricin Toxin
- Sinovac Files Clinical Trial Application With SFDA For Vaccine Against Hand, Foot, And Mouth Disease
- MRI Injury Prompts Recall of Medical Blanket
Random Posts
- Results From 8 Late-Breaking Clinical Trials Presented At Heart Failure 2009
- The National Association Of Boards Of Pharmacy (NABP) Moves To Next Phase Of Technician Recognition And Regulation
- Few Pharmacies Can Translate Prescription Labels Into Spanish
- CombinatoRx Presents Full Data On Synavive Phase 2 Knee OA Trial At EULAR 2009
- Celladon Provides MYDICAR(R) Program Update Of First-In-Human Trial For Advanced Heart Failure At American Society Of Gene Therapy Annual Meeting
- Immediate Tendonitis Relief Following Rotator Cuff Treatment
- New York Times Examines Debate Surrounding Use Of Experimental Treatments In Terminally Ill Patients
- Report Finds Racial Disparities In Prescription Drug Access, Use, Regimen Adherence
- TAU's Easy-To-Swallow Drug Restores Autoimmune Function In Diabetics
- Stem Cell Therapeutics Receives Clearance From Health Canada To Proceed With The Phase IIb Clinical Stroke Trial
Cardiovascular Events in Omalizumab Trial Prompt FDA Scrutiny
Posted by: admin in Pharmacy Drugs on August 22nd, 2009
WASHINGTON, July 16 — The FDA is reviewing safety data from an ongoing trial of the asthma drug omalizumab (Xolair) after interim results showed an excess of cardiovascular and cerebrovascular events among patients taking the drug.
The agency issued an early communication today about the review, which focuses on the Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS) trial.
The observational study is following some 5,000 asthma patients taking omalizumab — a monoclonal antibody targeting IgE antibodies — and 2,500 other patients treated with different medications.
“The interim data, submitted by the manufacturer of Xolair (Genentech), suggests a disproportionate increase in ischemic heart disease, arrhythmias, cardiomyopathy and cardiac failure, pulmonary hypertension, cerebrovascular disorders, and embolic, thrombotic and thrombophlebitic events in patients treated with Xolair compared to the control group of patients not given the drug,” according to the FDA’s announcement.
It did not provide specific numbers of events or other details.
The agency said it was not recommending that patients stop taking Xolair, nor is it going to demand label changes at this point.
“FDA has not made any conclusions regarding these data,” the announcement said.
Nor has the trial been stopped.
“The agency is working with Genentech to obtain further information and will continue to review the strengths and limitations of these interim results,” the FDA statement said. “For example, since EXCELS is an observational study, there could be differences in underlying risk factors for cardiovascular and cerebrovascular events between the two study groups.”
The agency urged healthcare professionals and patients to report side effects associated with omalizumab to its MedWatch safety program.
Omalizumab is currently approved for use by individuals at least 12 years old with moderate to severe persistent asthma who test positive for reactivity to a perennial airborne allergen, and whose symptoms are inadequately controlled with inhaled corticosteroids.
Related source:
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.
| Copyright 2009 |online pharmacy ambien no prescription buy xanax online no prescription online tramadol buying xanax online buy soma